Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Hims & Hers is shutting down the dermatology business it acquired four years ago, Business Insider has learned. On Friday, the telehealth company discontinued Apostrophe, the direct-to-consumer ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s expectations, but shares fell hard in after-hours trading ...

Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

Hims & Hers Health’s shares are extremely ... But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas ...

Apostrophe, a skin care telehealth brand headquartered in the Bay Area, is shutting down after almost four years under the Hims & Hers corporate umbrella. The skin care company, founded in ...

Telehealth company Hims & Hers Health (NYSE:HIMS) announced in Q4 CY2024, with sales up 95.1% year on year to $481.1 million. On top of that, next quarter’s revenue guidance ($530 million at the ...

Shares of direct-to-consumer telehealth platform Hims & Hers Health (NYSE: HIMS) have become a runaway freight train. The stock has returned nearly 20-fold returns from its 2022 lows, including a ...

Hims & Hers Health's stock has surged 205% since ... in website and mobile application development and internal-use software" investments in CapEx) gives the stock a price/FCF multiple of ~105x ...